Abstract
Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Current Pharmaceutical Biotechnology
Title: Antibody Aggregate Removal by Hydroxyapatite Chromatography
Volume: 10 Issue: 4
Author(s): Pete Gagnon and Kevin Beam
Affiliation:
Abstract: Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Export Options
About this article
Cite this article as:
Gagnon Pete and Beam Kevin, Antibody Aggregate Removal by Hydroxyapatite Chromatography, Current Pharmaceutical Biotechnology 2009; 10 (4) . https://dx.doi.org/10.2174/138920109788488833
DOI https://dx.doi.org/10.2174/138920109788488833 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Maximum Temperature Through a Yttrium Stabilized Zirconia Ceramic After Er,Cr:YSGG Laser Irradiation
Current Dentistry Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives
Current Drug Metabolism Innovative Therapeutic Strategies for Restoring Lymphocyte Functions in Septic Patients
Inflammation & Allergy - Drug Targets (Discontinued) Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy Modeling of Dopamine D2 Receptor - Overview of 35-Year Evolution
Current Medicinal Chemistry Structural Magnetic Resonance Imaging Findings in Posttraumatic Stress Disorder and Their Response to Treatment: A Systematic Review
Current Psychiatry Reviews Recent Developments in Nucleophilic Radical Addition to Imines: the Key Role of Transition Metals and the New Porta Radical-Type Version of the Mannich and Strecker Reactions
Mini-Reviews in Organic Chemistry Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo
Current Alzheimer Research Impaired Spatial Memory after Ketamine Administration in Chronic Low Doses
Current Neuropharmacology Evaluation of Plasma Homocysteine Levels as a Prognostic Factor for the Occurrence of Perioperative Myocardial Infarction in Coronary Artery Bypass Grafting: A Pilot Study
Vascular Disease Prevention (Discontinued) Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results
Current Cancer Drug Targets E-cigarettes: Impact of E-Liquid Components and Device Characteristics on Nicotine Exposure
Current Neuropharmacology The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis
Current Pharmaceutical Design Nuclear Factor Kappa B: A Potential Target for Anti-HIV Chemotherapy
Current Medicinal Chemistry An Enriched Population of CD45, CD34 and CD117 Stem Cells in Human Umbilical Cord Blood for Potential Therapeutic Regenerative Strategies
Current Neurovascular Research Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Current Drug Abuse Reviews Comprehensive Resources for Tomato Functional Genomics Based on the Miniature Model Tomato Micro-Tom
Current Genomics Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging
Current Pharmaceutical Design CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology